| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Margetuximab (anti-HER2)
CAS:1350624-75-7
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10710
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Margetuximab
CAS:1350624-75-7
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Margetuximab
CAS:1350624-75-7
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Margetuximab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
|
| | Margetuximab Basic information |
| Product Name: | Margetuximab | | Synonyms: | Margetuximab;Research Grade Margetuximab(DHC09604);Margetuximab (anti-HER2);Research Grade Margetuximab | | CAS: | 1350624-75-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Margetuximab Structure]() |
| | Margetuximab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Margetuximab Usage And Synthesis |
| Uses | Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer[1]. | | in vivo | Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 - 37 in mice model[1].
Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release[1].
Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile[1].
Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys[1].
| Male, IV (50 mg/kg) | Female, IV (50 mg/kg) | | Cmax (mg/mL) | 1.62 ± 0.10 | 1.70 ± 0.14 | | AUC0-￥ (mg·hour/mL) | 294.1 ± 53.2 | 314.2 ± 31.3 | | T1/2β (days) | 9.3 ± 1.8 | 9.7 ± 1.1 | | Clearance (mL/hour) | 0.43 ± 0.07 | 0.40 ± 0.04 | | VSS (mL) | 132 ± 2 | 127 ± 8 |
| | References | [1] Nordstrom JL, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069 |
| | Margetuximab Preparation Products And Raw materials |
|